DEVELOPMENT OF PRODRUG APPROACHES FOR LONG-ACTING NANOFORMULATIONS OF EMTRICITABINE-BASED REGIMENS
NIH/NIAID: 1F31AI129549-01A1; Amer Al-Khouja; 05/01/17 - 04/30/19
NIH/NIAID: 1F31AI129549-01A1; Amer Al-Khouja; 05/01/17 - 04/30/19
NIH/NIAID: 5R01AI120748-02; Marc Michael Baum (PI); 06/26/15 - 05/31/20
NIH/NIAID: 1R01AI131416-01; Andrew Martin Bellinger (PI); 03/22/17 - 02/28/22
NIH/NIAID: 4R01AI073146-09; Victor J. Garcia-Martinez (PI); 01/05/02 - 07/31/17
NIH/NIAID: 5R01AI117740-03; Christopher J. Destache (PI); 02/04/16 - 01/31/18
NIH/NIAD; 1R01AI131430-01; Soumya Rahima Benhabbour (PI); 03/06/17 - 02/29/20
Non-adherence to anti-retroviral therapy by HIV+ patients results in increased viral loads and risk of emergence of drug-resistant HIV strains. This poses a major public health threat. Lyndra Co. has developed an orally available, long-acting drug delivery system that it will now formulate to deliver anti-retrovirals.
NIH/NIAID; 4R01AI073146-09: Victor J. Garcia-Martinez (PI); 05/01/07 - 07/31/17
NIH/NIAID; 5UM1AI120184-02; Thomas Hope (PI); 07/07/15 - 06/30/20
NIH/NIAID 5R01AI120748-02; Marc M. Baum (PI); 06/26/15 - 05/31/20